

Healionics Awarded \$1.25M NIH Grant to Support Commercialization of STARgraft Vascular Graft

SEATTLE, WASHINGTON, USA, May 10, 2024 /EINPresswire.com/ -- [Healionics Corporation](#), a developer of biomaterial-based medical devices, today announced it has been awarded a \$1.25 million Small Business Innovation Research grant by the National Heart, Lung, and Blood Institute to support the commercialization of its STARgraft



STARgraft vascular graft

vascular graft. The grant was provided under the National Institutes of Health Commercialization Readiness Pilot Program, which provides additional technical assistance and late-stage R&D support not typically covered within small business awards to help products get to market.

“We appreciate NHLBI’s recognition of STARgraft’s potential to provide more reliable vascular access for dialysis patients,” said Mike Connolly, Chief Executive Officer of Healionics. “These funds will help us complete testing, pursue regulatory clearance, and prepare for market launch.”

About Dialysis and Vascular Grafts

More than 550,000 people in the United States suffer from kidney failure and require frequent dialysis to filter waste from their blood. Current methods of creating and maintaining regular bloodstream access for dialysis are risky, unreliable and costly, driving a significant portion of the \$50 billion the U.S. spends each year to treat kidney failure. A vascular graft (synthetic blood vessel) is often implanted to create an access site with sufficient flow rate for dialysis, but existing grafts frequently fail due to occlusion and/or infection. Healionics’ innovative STARgraft vascular graft, based on proprietary synthetic biomaterial technology, is designed to resist both problems.

About Healionics Corp.

Healionics is a privately held medical device company in Seattle that aims to improve the health, longevity, and quality of life of kidney failure patients, while reducing treatment cost.

www.healionics.com

Mike Connolly

Healionics Corp.

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/710364170>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.